Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscape

Lay summary

• Endometrial carcinoma (EC) classification and risk stratification have undergone a global transformation in the last decade, shifting from a reliance on poorly reproducible histomorphological parameters such as grade and histotype, toward a molecular classification that is consistent and biologically informative.

• Molecular classification enables reliable categorization of ECs, provides prognostic information, and is now beginning to drive clinical management, including surgery and adjuvant therapy.

• Within this framework, we now have the ability to further refine both the prognostic and predictive value of molecular classification.

• As we move toward the routine implementation of this classification system as a stratification tool for research, clinical trials, and patient care, it is imperative that access to these tests be equitable.

• Furthermore, continued education will be critical for patients and providers to understand the value that this molecular information provides.